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Exercise-Induced Mitrai Regurgitation and 
Antibiotic Prophylaxis Against Infective 
Endocarditis in Mitral Valve Prolapse 
I read with great interest he results of the study by Stoddard et al. (1) 
dealing with exercise-induced mitral regurgitation as a predictor of 
morbid events in patients with mitral valve prolapse. Their observation 
raises the important question of which patients with mitral valve 
prolapse should receive antibiotic prophylaxis against infective endo- 
carditis. 
According to the American Heart Association guidelines (2), only 
those patients with mitral valve prolapse and valvular regurgitation 
need antibiotic prophylaxis against infective endocarditis. But how do 
we define mitral valvular regurgitation? Patients with mitral valve 
prolapse may not have mitral regurgitation at rest but develop it after 
exercise; exercise-induced mitral regurgitation occurred in as many as 
33% of the patients tudied by Stoddard et al (1). Many a patient at 
rest may exhibit a murmur due to mitral regurgitation on one occasion 
but not on another (3). Mitral regurgitation considerably increases thc 
risk of infective endocarditis (4,5). Infective endocarditis complicating 
mitral valve prolapse causes considerable cumulative morbidity and 
incremental health care costs (6), but antibiotic prophylaxis against 
infective ndocarditis i highly cost-effective (7). Therefore, should not 
all patients with mitral valve prolapse receive antibiotic prophylaxis 
whether or not mitral regurgitation is evident on routine physical 
examination? 
TSUNG O. CHENG, MD, FACC 
Department of Medicine 
George Washington Univer~in' Medical ( emer 
2150 Penn.9'h'ania Avenue, NW 
l+izshington, D.C. 20037 
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R~ly 
We appreciate the very interesting question raised by Cheng concern- 
ing the potential need for antibiotic prophylaxis in all patients with 
documented mitral valve prolapse, given that mitral regurgitation in 
this condition may be transient and provoked by exercise (1). Althongh 
we cannot advocate the routine use of antibiotic prophylaxis in patients 
with mitral wtlve prolapse and no regurgitation during rest, we havc 
adopted this approach in the management of our patients with mitral 
valve prolapse. This approach is controversial, but we believe that it is 
supported by knowledge of the dynamic nature of mitral regurgitation 
in patients with mitral valve prolapse. However, it is possible that only 
patients with mitral valve prolapse with persistent compared with 
transient mitral regurgitation are at higher risk for endocarditis. The 
ultimate decision to use antibiotic prophylaxis in patients with mitral 
valve prolapse and no mitral regurgitation at rest must be made on an 
individual basis. Factors such as the nature of the invasive procedure, 
previous history of endocarditis and mitral valve redundancy may 
weigh heavily in the final decision to use or not to use antibiotic 
prophylaxis. Data from randomized clinical trials are lacking and are 
needed before definitive conclusions addressing the issue raised by 
Cheng can be reached. 
MARCUS F. STODDARD, MD, FACC 
Director. Non-lnvasive Cardiolo~,, 
Associate Professor o~ Medicine 
University of Louisville 
Louisville, Kentucl 9' 40202 
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International Comparisons of Waiting Times 
for Cardiovascular Procedures* 
As a Canadian clinical cardiologist, I read with interest he article by 
Carroll et al. ( 1 ) and the editorial comment by Ryan (2). I believe that 
the waiting times provided for Canadian catheterization laboratories 
and bypass surgery facilities are probably correct, and I agree that 
these waiting times are longer than they should be. My concern with 
the article, however, is whether it appropriately demonstrates the 
difference in access to cardiac care. Access is more than a matter of 
waiting time for operation, it is also a matter of whether one is 
considered worthy of being placed on the waiting list at all. 
In Canada. every patient who is considered a candidate for 
angiography is placed on the waiting list for angiography and subse- 
quently on the waiting list for bypass surgery. Whether the individual 
patient can afford to pay for bypass urgery is not a concern in Canada. 
My question is, How many patients who fit the profiles in the report by,. 
Carroll et al. do not get on the waiting list because they have n/oo 
insurance and cannot afford to pay for angiography or bypass surgery. 
I believe that it is better to have everyone wait somewhat longer rather 
than to provide a shorter waiting time for one group at the expense of 
no angiography or bypass surgery in the group with no money. 
I would be interested in a report that canvased cardiologists and 
primary' carc physicians, especially in some of the more economically 
disadvantaged regions, to determine how many U.S. patients do not 
make it onto the lists. Carroll et al. do quote an American Medical 
Association poll showing that the majority of Americans would prefer 
to spend more on health care and receive it quickly than wait longer for 
lower cost care. My question is, What about the Americans who cannot 
• The opinions expressed in this letter are those of the author and do not 
necessarily reflect those of the Department of National Defence, Canada. 
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afford to pay more (or pay anything) for their angiography or bypass 
surgery? How well are they served by the system? In Canada, we 
consider everyone with the clinical indications for coronary angiogra- 
phy or bypass surgery worthy of having the procedure, regardless of 
income. 
HENRY P. KAFKA, MD, FRCPC, FACC 
Lieutenant-Colonel 
Deputy Director 
Cardio-Pulmonary Unit 
National Defence Medical Centre 
Ottawa, Ontario K1A OK6, Canada 
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Reply 
Aday et al. (1) have defined access as those dimensions that describe 
the potential and actual, or realized, entry of a given population into 
the health care delivery system. Access to health care depends on many 
factors, such as race, culture, geographic location, financial and 
insurance status. For numerous reasons, equal access for all citizens to 
health care services in the United States has not yet been achieved. 
Kafka appropriately points out some of the differences between the 
Canadian and the U.S. health care systems and the fact that Canadians 
have "chosen" to emphasize access to primary care for all its citizens, 
apparently at the expense of "prolonged" waiting times for highly 
technical procedures. Certainly these issues must be addressed (as 
emphasized by Ryan [2]): How long a wait is too long? Are there 
negative consequences of too long a wait? Should the procedure in 
question be performed in the first place? However, I think that the 
fundamental issue is more a reflection of societal priorities. Do we as 
a society value health care services for all our citizens? Do we provide 
the financial resources o that all members of society, regardless of 
financial or insurance status, have access to primary and tertiary care 
in a timely manner? Canada has certainly taken a more committed role 
to universal access than has the United States. When the issue of what 
constitutes excessive waiting times are determined, it will be interesting 
to see whether or not Canadians will be willing to provide the financial 
support needed to develop and maintain a rapid-access primary and 
tertiary care system. For now, until we in the United States decide 
whether or not health care is a priority, the debate on how best to 
reform our health care system will continue with more unanswered 
questions than productive change. 
RICHARD J. CARROLL, MD, FACC 
Department of Cardiology 
Loyola University Medical Center 
2160 South First Avenue 
Maywood, Illinois 60153 
Reuse of Balloon Catheters for 
Coronary Angioplasty 
We congratulate Plante et al. (1) for their study in which they 
compared the outcome of balloon angioplasty in two institutions, with 
and without he strategy of reusing balloon catheters. We believe that 
some differences in the results are related to differences in the strategy 
of balloon dilation. It is evident from the report that in the reuse 
center, asmall balloon (smaller than the size of the artery) was used to 
predilate the artery initially. This technique xplains the difference in 
the number of balloon catheters used to dilate a single lesion: 2.4 in the 
reuse center and only 1.2 in the single-use center. The performance of
a reused balloon is not as good as that of a new balloon. However, this 
fact does not explain the observed ifference between centers and the 
number of balloons per lesion. In 90% of patients at the reuse center 
the lesion was crossed with the first attempted balloon catheter, yet 2.3 
balloons were used on average per lesion in these patients. Whether 
small-sized reused balloons were used initially to ensure crossing of 
severe narrowings or whether predilation was the preferred strategy 
regardless of reuse is not clear. 
At our institution 5,676 angioplasty procedures were performed 
over the past 10 years. During this period we were routinely using 
reused balloons, guiding catheters and accessory kits. Our reuse 
protocol is very similar to that described in the current report. We 
recently reported our results in a consecutive series of 2,069 angio- 
plasty procedures (2). A mean of 1.54 lesions were dilated per patient. 
We used an average of 1.95 balloons/patient (1.27 balloons/lesion); the 
number of balloons used per lesion is very similar to that reported 
from the single-use center. Each balloon was used an average of two 
times; thus, for each patient approximately one new and one reused 
balloon were used. Operators at our institution are free to choose a 
new balloon whenever they believe that crossing the lesion might be 
difficult or whenever high risk angioplasty is performed. 
On the basis of our experience, we believe that angioplasty can be 
safely performed with selective use of a reused balloon. Insofar as cost 
calculations are concerned, the cost of a single balloon is not as 
important as the cost of the total number of balloons used per dilated 
lesion. For example, balloon cost per lesion dilation will be greater in 
centers that use 2.4 balloons/lesion with an average of three reuse 
cycles compared with those that use 1.2 balloons/lesion with an average 
of one reuse cycle. The difference is the cost of two reuse cycles. 
A randomized study is needed to examine the safety and cost- 
effectiveness of reusing balloons. Three groups hould he compared: 1) 
no reuse; 2) wide use of reused balloons with predilation of severe 
lesions with small balloons; and 3) selective use of reused balloons. 
YOSEPH ROZENMAN, MD, FACC 
MERVYN S. GOTSMAN, MD, FACC 
Cardiology Department 
Hadassah University Hospital 
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